Diabetes Drugs In China Expand To Primary Healthcare Market
This article was originally published in PharmAsia News
Executive Summary
As China implements its medical reforms, diabetes drugs in the country will expand their market presence from hospitals to the primary healthcare segment, said Chow Lei Guen, Golden Sun vice-president